Pages that link to "Q38454174"
Jump to navigation
Jump to search
The following pages link to Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. (Q38454174):
Displaying 50 items.
- Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium (Q24311749) (← links)
- The enigmatic role of angiopoietin-1 in tumor angiogenesis (Q28191178) (← links)
- Angiopoietin signaling in the vasculature (Q28287317) (← links)
- A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma (Q28304566) (← links)
- Prostate cancer invasion and metastasis: insights from mining genomic data (Q30656758) (← links)
- Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2. (Q33277127) (← links)
- Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy (Q33779567) (← links)
- Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma (Q33866067) (← links)
- Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway (Q33896998) (← links)
- Lymphangiogenesis and lymphatic metastasis in breast cancer (Q33940058) (← links)
- Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. (Q34251293) (← links)
- Blood-brain barrier integrity and breast cancer metastasis to the brain (Q34495518) (← links)
- Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma (Q35083735) (← links)
- Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody (Q35092548) (← links)
- Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer (Q35144839) (← links)
- Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. (Q35171149) (← links)
- High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes (Q35263145) (← links)
- Gene expression profiling identifies clinically relevant subtypes of prostate cancer (Q35554359) (← links)
- Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody (Q35604097) (← links)
- Interleukin-6 Stimulates Defective Angiogenesis (Q35923153) (← links)
- Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma (Q35995721) (← links)
- Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis (Q36069142) (← links)
- Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors (Q36198192) (← links)
- The dynamic roles of angiopoietins in tumor angiogenesis (Q36429528) (← links)
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). (Q36480124) (← links)
- Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms (Q36994267) (← links)
- Expression of angiopoietin-TIE system components in angiosarcoma (Q36997066) (← links)
- Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer (Q37043828) (← links)
- Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression (Q37106787) (← links)
- Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial (Q37174690) (← links)
- In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors (Q37222836) (← links)
- Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche. (Q37340509) (← links)
- Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy (Q37509823) (← links)
- Targeting the ANGPT-TIE2 pathway in malignancy (Q37774852) (← links)
- AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer (Q37826430) (← links)
- Novel targets for VEGF-independent anti-angiogenic drugs. (Q37984612) (← links)
- Targeting angiopoietin-2 signaling in cancer therapy (Q38101997) (← links)
- Understanding and targeting resistance to anti-angiogenic therapies (Q38133568) (← links)
- Angiogenesis and acute myeloid leukemia (Q38160129) (← links)
- Control of the blood-brain barrier function in cancer cell metastasis (Q38511670) (← links)
- Gln-362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with α5β1 integrin (Q38955120) (← links)
- Therapeutic targeting of the angiopoietin-TIE pathway (Q39321127) (← links)
- Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor (Q39619307) (← links)
- Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway (Q40490472) (← links)
- Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer (Q42467882) (← links)
- Angiopoietins lack of prognostic significance in ductal mammary carcinoma (Q42867904) (← links)
- Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. (Q44680433) (← links)
- Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis (Q44957244) (← links)
- Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population (Q46211892) (← links)
- Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report (Q46666106) (← links)